Slides
Page 1
Corporate Deck September 2026
Page 2
Disclaimers 2 We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing and phase of development, costs, design and conduct of, and data readouts from, our ongoing and planned preclinical studies and clinical trials for our product candidates, the potential to conduct an adjuvant or ablative Phase 3 trial in IR NMIBC, the timing and likelihood of regulatory filings and approvals for our product candidates, the potential to develop product candidates and for them to be first-in-class or game changers, and the potential safety and therapeutic benefits of our product candidates, including projected or modelled response rates or other data points, our ability to commercialize our product candidates, if approved, the pricing and reimbursement of our product candidates, if approved, and the potential for them to be blockbusters, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: initial or interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient or final data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; preliminary pharmacokinetic, pharmacodynamic and exposure-response analyses may not be predictive of future clinical outcomes or later-stage studies; early clinical observations from SURF303, including those from an individual participant, may not be predictive of future results; the safety and than we expect; unstable market and economic conditions, geopolitical instability, war, inflation, interest rate increases and changes in healthcare legislation, tariffs and trade policies may adversely affect our business and financial condition and the broader economy and biotechnology industry; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. Pooled and Modeled Data: Certain of the safety and efficacy data described in this presentation reflect a pooled analysis of results from separate dose cohorts across our SURF301, SURF302 and healthy volunteer studies. Differences exist between subject characteristics and other factors, and caution should be exercised in drawing any conclusions from such data as pooled data is inherently limited and such data may not be directly comparable nor predictive of future results. In addition, our modeled projections for a potential adjuvant Phase 3 study rely in part on clinical activity and exposure data observed to date in SURF302, and there can be no assurance that the actual results will not materially differ from our projections, whether based on the inherent limitations of assumptions used in model extrapolation or differences in trial design, statistical powering, or the size or characteristics of subject populations or other factors. efficacy observed to date may not continue in ongoing or future studies; the potential for proof-of-concept results to fail to result in successful subsequent development of oral dabogratinib; later developments with the FDA may be inconsistent with prior feedback from the FDA; feedback from global health authorities on a potential Phase 3 trial in IR NMIBC in the adjuvant or ablative setting may not be as anticipated; we are early in our development efforts, and the approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; potential delays in the commencement, recruitment, enrollment, data readouts, and completion of preclinical studies and clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; our dependence on third parties in connection with manufacturing, research and preclinical testing; we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; acceptance by the FDA of INDs or of similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates; an accelerated development or approval pathway may not be available for oral dabogratinib or other product candidates and any such pathway may not lead to a faster development process; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; unfavorable results from preclinical studies; we may not realize the benefits associated with orphan drug designation, including that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained or from the rare pediatric disease designation, including receipt of a Priority Review Voucher (PRV) or any value therefrom; regulatory and legislative developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and proprietary technologies; our ability to establish marketing and sales capabilities to successfully commercialize any approved products; we may use our capital resources sooner FORWARD-LOOKING STATEMENTS AND MARKET DATA
Page 3
Gearing up for potential pivotal trials in 3 blockbuster indications 3 ACH: Achondroplasia; IR NMIBC: Intermediate Risk Non-Muscle-Invasive Bladder Cancer; LG UTUC: Low Grade Upper Tract Urothelial Carcinoma; ML Marker Lesion; ORR: Overall Response Rate; BOR: Best overall Response; CR: Complete Response; DL: Dose Level All TYRA small molecule inhibitors are for investigational use only Differentiated Molecule 3 Potential Blockbuster Indications Validated Target FGFR3 alterations drive conditions with high unmet needs IR NMIBC – Adjuvant Ph3 Initiation EXPECTED 2027 NASDAQ: TYRA CASH: $353.9M (As of 2Q26) ACH – Initial results (n=~25 sentinel DL1-5) End of 1Q27 LG UTUC – Initial results 2027 The first oral, once-daily, highly selective FGFR3 inhibitor DABOGRATINIB 60mg PoC IR NMIBC Patients All MLs: 79% ORR and 64% BOR CR rate (n=14) Single MLs: 100% ORR & 75% BOR CR rate (n=8)
Page 4
Our expertise in FGFR biology creates a differentiated pipeline 4 Discovery IND- Enabling 1 2 3 Phase Estimated Annual US Addressable1Dabogratinib Target ~3KLG UTUC IR NMIBC Other TYRA-430 HCC ~15K TYRA-200 ICC FGFR3 FGFR3 FGF19 FGFR1–3 ~6K ~35K CHEMISTRY DESIGN ACH FGFR3 ~3K LG UTUC: Low Grade Upper Tract Urothelial Carcinoma; IR NMIBC: Intermediate Risk Non- muscle Invasive Bladder Cancer; ACH: Achondroplasia; HCC: Hepatocellular Carcinoma; ICC: Intrahepatic Cholangiocarcinoma 1. Represents FGFR3/FGFR2/FGF19+ incidence and recurrences for ONC and prevalence for ACH FDA clearance for dabogratinib Phase 2 INDs in ACH, IR NMIBC and LG UTUC based on Ph1 data from SURF301 TYRA retains an active FGFR3 discovery program
Page 5
TYRA’s highly selective FGFR3 inhibitor Our development paths in Urology and ACH 5
Page 6
6 FGFR3 drives unmet need in multiple large market opportunities Dabogratinib Has the potential to address these indications Oncology figures represent US incidence and recurrences; skeletal dysplasias represent US pediatric prevalence; Sources: US 2024 Census; Vajo, 2000; van Rhijn, 2010; Mayr, 2022; Kacew, 2020; DR/Decision Resources LLC 2025; CancerMPact® Patient Metrics and Oracle Life Sciences analysis; Ravvaz, 2019, Caputo, 2020, Check, 2019, Ritch, 2020, Lyall, 2023; Vedder, 2014; Sfakianos, 2015, Moss, 2017; Nassar 2019 Dabogratinib is an investigational product and has not been approved by any governmental body for any therapy or indication INTERMEDIATE RISK NMIBC ~70% FGFR3 | ~35,000/yr (US) TOTAL UROTHELIAL CARCINOMA (UC) ~45% FGFR3 | ~80,000/yr (US) LOW GRADE UTUC ~85% FGFR3 | ~3,000/yr (US) ACHONDROPLASIA (ACH) TOTAL FGFR3-RELATED SKELETAL DYSPLASIA ~99% FGFR3 | ~3,000/yr (US) >40,000/yr (US)
Page 7
Our SNAP platform was able to address an intractable problem 7 FGFR isoform selectivity 3.0Å cross-sections Subtle, but distinct differences at key interaction zones along the pocket walls Dabogratinib FGFR3 specific inhibitor dozens of high-resolution crystal structures MOLECULAR MODEL CRYSTALLOGRAPHY FGFR1 FGFR3 FGFR1FGFR3
Page 8
Dabogratinib is a potential first-in-class, selective FGFR3 inhibitor 8 All experiments conducted under identical conditions, tested in duplicate. Note: Dabogratinib FGFR3 selectivity is defined by its activity against FGFR3 relative to its activity against the other individual FGFR isoforms. Erdafitinib and futibatinib are FGFR1, 2, 3, 4 or Pan-FGFR inhibitors and infigratinib and pemigatinib are selective FGFR1, 2, 3 inhibitors (Loriot, 2023; Goyal, 2023; Savarirayan, 2024; Vogel, 2024). . 0 20 40 60 80 120 Selectivity observed for dabogratinib vs. approved/late-stage clinical compounds: in vitro Ba/F3 Cellular IC50 (nM) FGFR1 FGFR2 FGFR3 FGFR4 PF E I D PFE I D PE I PF E ID 459142 FD D dabogratinibI infigratiniberdafitinibE pemigatinibPfutibatinibF 100 19x 63x 55x FGFR1 4.2x 4.9x 2.4x 2.2x FGFR2 1.4x 1.3x 0.8x 0.8x FGFR4 14x 7.6x 27x 67x IPFE IC50 (nM) Fold selectivity from FGFR3
Page 9
TYRA’s highly selective FGFR3 inhibitor Our development paths in Urology and ACH 9
Page 10
High FGFR3+ rate drives an outsized opportunity in IR NMIBC 10 ~185K ALL BLADDER Total seeking treatment each year Percentage FGFR3+ ~45%820K+ people living with bladder cancer and UTUC in the US FGFR3+ seeking new treatment FGFR3+ Rate Sources: van Rhijn, 2010; Mayr, 2022; Kacew, 2020; Sfakianos, 2015, Moss, 2017; Nassar 2019; MIBC, mUC; All Bladder Prevalence Source: SEER; MIBC and mUC Patients Seeking New Treatment Source: DR/Decision Resources LLC 2025 Epidemiology Figures; NMIBC and UTUC Patients Seeking New Treatment Source: CancerMPact® Patient Metrics and Oracle Life Sciences analysis; Ravvaz, 2019, Caputo, 2020, Check, 2019, Ritch, 2020, Lyall, 2023; Vedder, 2014 80200 60 ~70%IR NMIBC No patient-friendly oral Tx to reduce recurrences ~50K LG UTUC ~3.5K ~85% ~3.0KNo patient-friendly oral Tx to reduce risk of renal loss 40 ~80K ~35K
Page 11
11 IR NMIBC
Page 12
Most LG IR NMIBC patients don’t receive Tx to prevent recurrence 12 ~70% forego adjuvant Tx1…. IVe Tx …despite efficacy 2… 1. 2025 data for LG IR NMIBC patients who underwent bladder tumor resection captured in Cardinal Health Specialty Networks PPS Analytics Patient Population Health Management Platform; IVe Tx includes induction and/or maintenance 2. Data across NMIBC risk categories and IVe Chemo treatment durations (Huncharek, 2000); 3. Data for IR NMIBC patients treated with TURBT+SoC IVE chemo (Matulewicz, 2020); 4. TYRA Market Research, 2026 44% Recurrence Risk Reduction Patients Treated with Adjuvant IVe Chemo ~70% Watch & Wait ~30% This may be why “No one likes anything shoved up their urethra” ―Community urologist4 0 10 20 30 40 6mo 12mo 24mo Recurrence Progression 40 30 20 2 3 5 6–30 times …and a high rate of recurrence3
Page 13
FGFR3+ patients benefit from sustained FGFR3 inhibition 13 FGFR3+ VALIDATED TARGET IN IR NMIBC FGFR3-FGFR3+ Median RFS2 (months) 39.9 16.1 0 10 20 30 40 ~15K FGFR3– Seek Treatment1 (per year) ~35K FGFR3+ ~50K 2. Adapted from Meeks, 2026 (AUA); RFS across Low Grade NMIBC More Recurrent 1. Van Rhijn, 2010; CancerMPact® Patient Metrics and Oracle Life Sciences analysis; Ravvaz, 2019, Caputo, 2020, Check, 2019, Ritch, 2020, Lyall, 2023; Vedder, 2014 EVIDENCE TAR-210 Pan-FGFR Pretzel 3 of 4 evaluated recurred within 3 mo after 12 mo total Tx course of TAR-2103 Oral Erdafitinib Pan-FGFR 100% durability while on therapy 100% durability while on therapy SUSTAINED INHIBITION MAINTAINED RESPONSES 4 of 6 patients who discontinued treatment recurred within 1 year 4 3. Vilaseca, 2024 (AUA) 4. Daneshmand, 2025 (European Urology) Note: the oral Erdafitinib trial was stopped early due to slow accrual in part due to concerns regarding systemic toxicities (Catto, ESMO 2023)
Page 14
Dabo is uniquely positioned to expand Tx beyond procedures 14 ADJUVANT IVe Tx IN DEVELOPMENT ZUSDURI1 (Mitomycin hydrogel) 6 Total instillations Weekly for 6 weeks CRETOSTIMOGENE (Oncolytic adenovirus) 14 Weekly for 6 weeks Then quarterly for 1–3 weeks TAR-210 (erdafitinib “pretzel”) 8Quarterly for 12 months All five require multiple urethral violations with dwell times 1. Zusduri approved for IR NMIBC and disclosed plans for UGN-103 adjuvant study (Urogen Press Release, August 5, 2026) NDV-01 (gemcitabine-docetaxel) 32 Total instillations Weekly for 12 weeks, then monthly Adstiladrin (nadofaragene firadenovec-vncg) 8 Quarterly over 2 years Dabogratinib ORAL DEVELOPMENT Only one: a targeted therapy TARGET PROFILE efficacious and tolerable to enable chronic Tx
Page 15
LG IR NMIBC, Marker Lesion Study Dabogratinib (TYRA-300) NCT06995677 Adults (≥18 years) FGFR3 activating gene alterations confirmed by urine or tissue test IR NMIBC based on AUA Guidelines, 2024 • Recurrence w/in 1 year, LG Ta • Solitary LG Ta >3cm • LG Ta, multifocal • LG T1 At least 1 marker lesion; total aggregate ≥3 mm ≤12 mm 1. Optional if needed, start after initial data review of 50 mg QD (dosed once daily) and 60 mg QD Primary EndpointCR at 3 mo • Best Overall Response (BOR) • Time to recurrence • Median duration of response • Recurrence free survival (RFS) • Progression free survival (PFS) • Safety and tolerability Abbreviations: LG, low grade; IR NMIBC, intermediate risk non-muscle invasive bladder cancer; R, randomized; CR, complete response; FGFR3, Fibroblast Growth Factor Receptor 3; QD, once daily; ML, marker lesion Cohort A N=30 | 60mg QD Cohort B Cohort C N=30 | If needed1 Secondary Endpoints Key Eligibility Criteria No CR at 3 mo CR at 3 months Continue on study treatment up to 24 mo. May continue if ML reductions at mo 3 are >50% R 1:1 N=30 | 50mg QD Prescreening includes: urine sample for tumor genomics and/or consent to provide prior tumor genomics report or archival tissue and consent to allow marker lesion(s) to remain in situ SURF302 was designed to select a dose for Phase 3 15
Page 16
100% ORR at 60mg in single marker lesion patients 16 PHASE 3 Planned to evaluate Dabogratinib’s potential to prevent new lesion growth after tumor removal Evaluating Dabogratinib’s potential to shrink and ablate all lesions in bladder 60mg Single Marker Lesion (ML) Data 1. Best Overall Response (n=8) 100% ORR 75% CR 2. Safety data supports chronic dosing potential 3. High confidence in adjuvant Ph3 potential ADJUVANT ALL TUMORS REMOVEDPHASE 2 ABLATIVE TUMOR(S) REMAIN Implications from Phase 2 Plan to take 60mg forward in Adjuvant Phase 3 study vs placebo See disclaimer on pooled and modeled data. Explore upside of 70mg in ablative setting, given dabo’s favorable safety data to date Multiple ML (ablative expansion)
Page 17
17 IR NMIBC SURF302 Data and Phase 3 Dose Selection
Page 18
SURF302 enrolled a highly recurrent, undertreated population 18 De Novo 2 (5) Recurrent 38 (86) DE NOVO OR RECURRENT2 n=44 Range (26-82) 70 (yrs)MEDIAN AGE SEX AT BIRTH Male 31 (71) n (%) Mutation 40 (91) Fusion 5 (11) FGFR3 ALTERATION1 <20 29 (66) >20 14 (32) AGGREGATE LESION SIZE (mm)2 PRE-RESECTION MARKER LESION NUMBER1 n (%) <10 32 (73) >10 11 (25) MARKER LESION2 SIZE (mm) n=44 TURBT Range (0−10) 2 Range (0−7) 0 1 27 (61) >1 16 (36) Intravesical (IVe) Tx3 MEDIAN PRIOR: Safety analysis population: all randomized subjects who received study treatment as of August 31, 2026 data cutoff 61% of patients had no prior lines of IVe Tx2 1. 2 subjects had both mutations and fusions; 1 patient had neither entered yet in current database 2. Data pending database entry as of the data cutoff; categories may not sum to 100% of n=44 3. Non-wash IVe Treatment
Page 19
Favorable safety and tolerability data support chronic Tx potential 19 Adverse Events Were Manageable • No clinically significant hyperphosphatemia, nail toxicity or ocular toxicity • Low frequency of transaminase TEAEs 1. Cutoff based on individual cohorts; represents max grade per patient 2. >10% in 60mg cohort only TEAEs in Patients Treated with Dabogratinib, n (%) 60 mg (n=22) 50 mg (n=22) All Discontinuations 0 (0) 1 (5) All Dose Reductions 0 (0) 0 (0) All Dose Interruptions 4 (18) 1 (5) Related Interruptions 2 (9) 1 (5) n (%) AE-related Safety analysis population: all randomized subjects who received study treatment as of August 31, 2026 data cutoff. No grade 4 or 5 events 60 mg (n=22) 50 mg (n=22) Gr. 1 Gr. 2 Gr. 3 Gr. 1 Gr. 2 Gr. 3 Participants with at least one TEAE, n(%)1 7 (32) 5 (23) 3 (14) 9 (41) 4 (18) 2 (9) Gr. 3 TRAE, n(%)1 — 2 (9) TEAEs in >10% in each cohort, n(%) Gr. 1 Gr. 2 Gr. 3 Gr. 1 Gr. 2 Gr. 3 Fatigue 8 (36) — — 4 (18) 1 (5) — Dry eye2 5 (23) — — 1 (5) — — Diarrhea 4 (18) 2 (9) — 4 (18) — — Urinary Tract Infection2 — — 3 (14) — 1 (5) — Dysgeusia2 3 (14) — — — — — Faeces Soft2 3 (14) — — 2 (9) — —
Page 20
GI events were limited and transient 20 Diarrhea TEAEs in all safety evaluable patients (n=44) • No dose reductions or interruptions from treatment-related diarrhea • All cases were transient or intermittent • One patient with history of diverticulosis has stayed on therapy >14mo 50 mg 60 mg Time on treatment (months) Grade 1 Grade 2 On Therapy GLP-1 related Intermittent AE Safety analysis population: all randomized subjects who received study treatment as of August 31, 2026 data cutoff. Ongoing AE
Page 21
60mg demonstrated robust clinical activity with a dose response 21 3-mo BOR ORR 79% (11) 79% (11) CR 57% (8) 64% (9) PR 21% (3) 14% (2) 60mg 3-mo & BOR ORR 67% (8) CR 33% (4) PR 33% (4) 50mg • Clear dose response observed • Initial 60mg PR with a 6-mo assessment converted to a CR • All 3-mo CRs with 6-mo assessment remain in response at 6-mo (n=5) FINDINGS n=141 n=121 PR: ≥50% reduction in ML aggregate size and no new lesions BOR: Best Overall Response August 31, 2026 cutoff 1. Efficacy evaluable analysis set: All randomized participants who received study treatment and have undergone at least the month 3 disease assessment.
Page 22
50 mg 60 mg Baseline (Pre-resection) Marker Lesion (Post Resection) Evidence of response maintenance and maturation 22 Lesion Count Complete Response (CR) Partial Response (PR) Non CR Remains on study drug Discontinuation No. of lesions pre/post resection 1−8 August 31, 2026 cutoff, efficacy evaluable analysis set: All randomized participants who received study treatment and have undergone at least the month 3 disease assessment.
Page 23
Model projects likely plateauing of adjuvant efficacy above 60mg 23 AUCss ≤2500 n=12 >2500 n=14 BOR 58% (7) 86% (12) CR 25% (3) 71% (10) PR 33% (4) 14% (2) 86%ORR at >2500 AUCss Response Rate by AUC across 50 and 60mg % Patients predicted >2500 AUCss Predicted Steady State AUC by Dose (n=172) 30,000 10,000 1,000 300 3,000 AUCss ng·hr/mL (Log10) 30 40 50 60 70 80 Dose (mg QD) 2% 21% 58% 82% 94% 98% Data pooled from SURF302 50 and 60mg doses PR: ≥50% reduction in ML aggregate size and no new lesions BOR: Best Overall Response August 31, 2026 cutoff, efficacy evaluable analysis set: All randomized participants who received study treatment and have undergone at least the month 3 disease assessment. Population PK model developed using data from 172 participants across SURF301, SURF302 and healthy volunteer study and used for exposure (AUC, Cmax, Cmin) prediction for individual patients in SURF302 study AUC target derived from preliminary E-R analyses of pooled data of 50 mg and 60 mg dose cohorts from SURF302 study; AUC 2500 ng·h/mL corresponds to C avg of ~100 ng·h/mL, consistent with the enzymatic IC 50 of dabogratinib AUCss 2500* *estimated IC50 (Cavg) See disclaimer on pooled and modeled data.
Page 24
Clinical activity improved in patients with single marker lesion 1 ML n=16 ≥2 MLs n=10 BOR 94% (15) 40% (4) CR 56% (9) 40% (4) PR 38% (6) 0% (0) 94%ORR with 1 ML Response Rate by ML across 50 and 60mg 3-mo BOR ORR 100% (8) 100% (8) CR 63% (5) 75% (6) PR 38% (3) 25% (2) 60mg with 1 ML n=8 Data pooled from SURF302 50 and 60mg doses PR: ≥50% reduction in ML aggregate size and no new lesions BOR: Best Overall Response August 31, 2026 cutoff, efficacy evaluable analysis set: All randomized participants who received study treatment and have undergone at least the month 3 disease assessment. 24See disclaimer on pooled and modeled data. all but one had multiple MLs; of the 6 non-responders with ≥2MLs, only one had AUC >2,500 ng·h/mL all achieved AUC >2,500 ng·h/mL Of the 7 non-responders across both doses Of the 4 responders with multiple marker lesions
Page 25
Modeling supports our confidence in planned adjuvant Ph3 25 1. Derived from Meeks et al., AUA 2026; 35.6%, exponential, FGFR3-alt LG NMIBC (mRFS = 16.1 mo, n = 117); 2. Calculation; 3. Assumption 0 6 12 18 0 20 40 60 80 100DFS Probability (%) Time (mo) Modeled DFS Curves4 λ = –ln(DFS₂₄) / 24 4. Illustrative model based on stated assumptions; not predictive of clinical outcome =+ x DFS24DFS0 (1-DFS0) [(DoR x CR) (DoR x PR)]+ 24 72% 55% 36% Dabo model Scenarios See disclaimer on pooled and modeled data. Pooled conservative 36%1 64%2 [(0.63 x 50%3) (0.03 x 23%3)] 55%2+ = 0.6 36% Placebo 55% 60mg conservative [(0.83 x 64%3) (0.43 x 14%3)] 72%2+ = 0.3 81% 60mg with 1 ML [(0.83 x 75%3) (0.43 x 25%3)] 81%2+ = 0.2 Implied Hazard Ratio vs. Placebo FGFR3-driven Efficacy DFS: Disease Free Survival; DoR: Duration of Response
Page 26
26 IR NMIBC Market Opportunity
Page 27
Our mission is to make dabogratinib the clear first-line choice WIN ON EFFICACY AND CONVENIENCE 27 POTENTIAL FOR A DAILY ORAL Replace repeat catheterizations/instillations LG IR NMIBC adjuvant patients1 1. 2025 data for LG IR NMIBC patients who underwent bladder tumor resection captured in Cardinal Health Specialty Networks PPS Analytics Patient Population Health Management Platform; IVe Tx includes induction and/or maintenance IVe Tx ~70%Watch & Wait ~30% SWITCH CONSIDERATIONS • Instrumentation fatigue • Potential for continued DFS with oral Tx
Page 28
COMPETE ON CONVENIENCE Preference for oral Orgovyx transformed the ADT market Aligned Practice Economics Streamlined Operations IOD contracting + limited distribution3 enable economics equivalent to Part B Nurses and treatment rooms removed 1. Data for prostate cancer patients treated with ADT captured in Cardinal Health Specialty Networks PPS Analytics Patient Population Health Management Platform; 2. Collins, 2025; 3. Orgovyxhcp.com accessed 5/27/26 ADT: Androgen Deprivation Therapy RI: Relative Importance 28 100% 2021 2025 Community Urology Patient Share1 0% 20% 40% 60% 80% 52% 48% 92% 8% Patient Preference2 Testosterone surge after initiation of ADT Mode of admin. Cardio. event risk 0 10 20 30 RI estimates (%) 1 3 2 Oral Orgovyx Injectable ADT
Page 29
Our mission is to make dabogratinib the clear first-line choice EXPAND THE MARKET 29 POTENTIAL FOR A DAILY ORAL Reduce recurrence and surgery Reduce 3-month cystoscopy burden POTENTIAL FOR A DAILY ORAL Replace repeat catheterizations/instillations LG IR NMIBC adjuvant patients1 1. 2025 data for LG IR NMIBC patients who underwent bladder tumor resection captured in Cardinal Health Specialty Networks PPS Analytics Patient Population Health Management Platform; IVe Tx includes induction and/or maintenance IVe Tx ~70%Watch & Wait ~30% SWITCH CONSIDERATIONS • Instrumentation fatigue • Potential for continued DFS with oral Tx WIN ON EFFICACY AND CONVENIENCE
Page 30
66% 71% 71% 76% 76% 76% 76% 76% 79% 84% Fewer clinic visits Treat at home Less discomfort Catheter insertion Less travel Less time away Control of Tx time Need less help Sense of control Greater privacy Research indicates patients would strongly value an oral therapy 30 LIFESTYLE APPEAL OF A DAILY ORAL PILL1 How appealing is each of the following factors related to an oral pill that you take daily?* Greater privacy Sense of control and empowerment Less need for help from family or friends More control over when treatment is taken Less time away from work or other activities Less travel No catheter insertion Less discomfort Ability to take treatment at home Fewer clinic visits Full prompts Options 1. Not at all 2. Slightly 3. Moderately 4. Very 5. Extremely Top 2 (Very, Extremely) * 1. August 2026 survey of N=38 IR NMIBC patients, TYRA Market Research on File (study ongoing) Lower 3 If oral treatment still required the same cystoscopy schedule for monitoring your remission, how much benefit would taking treatment at home provide? TREATMENT APPEAL1 Options 1. No benefit 2. A small benefit 3. A moderate benefit 4. A large benefit 5. A very large benefit 77%Top 2 (Large, Very large) Lower 3
Page 31
57% 59% 61% 63% 67% 71% 75% 75% Urologists prioritize efficacy and relief from invasive procedures 31 1. August 2026 survey of N=51 Urologists (78% community-based), TYRA Market Research on File (study ongoing) Durable responses over time in IR-NMIBC Reduction in invasive procedures such as TURBT/Fulguration A reduction in the overall burden of attending treatment appointments (travel, time, transportation, cost) A less invasive treatment experience Strong reduction in recurrence risk Reduction in repeat catheterization and intravesical drug administration Favorable tolerability with a low toxicity burden Ability to be used effectively in both adjuvant and ablative treatment settings Full prompts* To what extent, if at all, would you consider each of the following an unmet need in the management of IR-NMIBC?* UNMET NEEDS IN IR NMIBC1 Options 1. No unmet need at all 2. 3. 4. Moderate unmet need 5. 6. 7. Extremely high unmet need Top 3 (5,6,7) Top 3 Durable response Fewer invasive procedures Reduced overall burden Less invasive experience Reduced recurrence Fewer repeat catheterizations Favorable tolerability Adjuvant and ablative use The majority of urologists would recommend patients try oral before pretzel
Page 32
Our mission is to make dabogratinib the clear first-line choice EXPAND THE MARKET 32 POTENTIAL FOR A DAILY ORAL Reduce recurrence and surgery Reduce 3-month cystoscopy burden POTENTIAL FOR A DAILY ORAL Replace repeat catheterizations/instillations LG IR NMIBC adjuvant patients1 1. 2025 data for LG IR NMIBC patients who underwent bladder tumor resection captured in Cardinal Health Specialty Networks PPS Analytics Patient Population Health Management Platform; IVe Tx includes induction and/or maintenance IVe Tx ~70%Watch & Wait ~30% WIN ON EFFICACY AND CONVENIENCE >$5BILLION TOTAL POTENTIAL MARKET SIZE2 2. Represents estimated full potential FGFR3+ IR NMIBC market at full penetration of branded agents; based on LEK research.
Page 33
33 UTUC
Page 34
UPPER TRACT UROTHELIAL CARCINOMA Same histology as bladder cancer. Affects upper urinary tract including renal pelvis and ureters. Dabogratinib could address specific unmet needs in LG UTUC 34 LOW GRADE UTUC FGFR3+ seeking new treatment each year Ureter length, orientation, and intra-renal anatomy presents challenges with diagnosis and treatment Repetitive, burdensome surgeries and procedures with high rates of complications and potential for loss of kidney ANATOMY TREATMENT UNMET NEED No high grade on biopsy or cytology ~3,000~85% Renal pelvis Calyx FGFR3+ Oncology figures represent US incidence and recurrences; Oracle Life Sciences analysis; Sfakianos, 2015, Moss, 2017; Nassar 2019
Page 35
Current kidney-sparing endoscopic surgery SoC has drawbacks 35 ≤25% missed due to challenging anatomy and ~30% multifocality MISSED TUMORS RECURRENCE AND PROGRESSION KIDNEY REMOVAL SIGNIFICANT RISKS SURGERY ALL LG TUMORS ~35–50% recur within 3 years LG TUMORS >2cm 90.5% recur (median 4.9 mo) 31.7% progress (median 26.3 months) POOR OUTCOMES General anesthesia Intra- and post-operative complications After recurrence or progression, proceed to radical nephroureterectomy (Can result in chronic dialysis, and increased CV morbidity, mortality) Yamany, 2015; Shvero, 2021; Scotland, 2018; Cutress, 2012
Page 36
Jelmyto, is more effective but comes with many limitations 36 Efficacy 58% CR rate 56% 12-month DoR Safety 58% Ureteric obstruction 41% Flank pain 34% Hematuria 34% UTI 25% Renal dysfunction 24% discontinuation Eligibility Renal pelvis (not ureters) Tumors 5–15mm in size Administration 6 instillations: • Ureteral catheter with fluoroscopy or antegrade nephrostomy tube • Local anesthesia Preparation • >40 steps • Refrigeration and reconstitution • 45–60 minutes JELMYTO package insert and website accessed September 5, 2025
Page 37
First LG UTUC patient has been dosed in Dabogratinib Ph2 Study 37 LG UTUC, Marker Lesion Study Dabogratinib (TYRA-300) NCT07265947 Adults (≥18 years) LR, LG UTUC based on AUA Guidelines, 2024 • No high-grade histology on biopsy or cytology • No invasion or adenopathy on imaging At least 1 marker lesion; total aggregate ≥5mm Q3 month disease assessments to 18 mo; Q6 month thereafter. Treatment allowed up to 24mo. Patients who do not achieve a CR at 3mo may continue to mo 6 if ML reductions at mo 3 are >50% Primary Endpoint • CR within 6 mos in all comers • DOR • Safety and tolerability • Conversion of unresectable to resectable disease Abbreviations: LG, low grade; LR, low risk; UTUC, upper tract urothelial carcinoma; R, randomized; CR, complete response; DOR, duration of response; FGFR3, Fibroblast Growth Factor Receptor 3; QD, once daily; ML, marker lesion Cohort A N=25 | 80mg QD Cohort B N=25 | 60mg QD Cohort C N=25 | If needed1 Secondary Endpoints Key Eligibility Criteria CR within 6 months in FGFR3+ patients Prescreening includes: urine sample for tumor genomics, tissue sample for retrospective sequencing for FGFR3-gene activating alterations, consent to provide prior tumor genomics report and consent to allow marker lesion(s) to remain in situ R 1:1 Stratification by aggregate tumor baseline size prior to resection <1.5cm vs. ≥1.5cm DOSE FINDING POTENTIAL PIVOTAL N=75–100 Optimal Dose Ph2a Ph2b 1. Optional if needed start after initial data review of 60 mg QD and 80 mg QD, as needed
Page 38
60mg activity extends from IR NMIBC to first LG UTUC patient 38 73-year-old male, 60mg QD COMPLETE RESPONSE Disease History LG UTUC, Initial diagnosis date: 2024 Medical History T2DM, BPH, CAD, cataracts, retinal pigment epithelial mottling, UTI (ongoing at C1D1) Prior UTUC treatment Fulguration (x3); Jelmyto ( 2025; completed Tx, recurrence 2026) Renal pelvis: 5 mm Marker Lesion Apr 2026 Data as of August 31, 2026 Aug 31 2026 No dose interruptions or reductions 3mo CR Jun No adverse events reported as of data cutoff No clinically significant changes in lab values from BSL May Jul Aug
Page 39
39 ACHONDROPLASIA
Page 40
Inhibiting FGFR3 may benefit people with skeletal dysplasia 40 FGFR3 Over-activation of this protein in bone growth plates underlies both ACH and HCH 6 5 4 3 2 1 ~5’9” 1.76m1 ~5’4” 1.63m1 ~4’3” 1.30m2 ~4’7” 1.39m3 ACH HCH 1. CDC Vital and Health Statistics (represents average US male and female heights for ages 20-29); 2. Hoover-Fong, 2021 (represents average ACH adult male height); 3. Cheung, 2023 (represents average HCH female height at age 16)
Page 41
ACH can result in serious clinical complications 41 Infants can face serious complications related to critical foramen magnum stenosis1,3 Children and adults may experience pain, multiple surgeries, and functional limitations (e.g., reach, stride) 1. Pauli et al., 2019; 2. Ornitz and Legeai-Mallet, 2017; 3. Hecht et al., 1987 FGFR3 G380R gain of function mutation drives ~99% of ACH1,2 FGFR3 inhibits chondrocyte proliferation and differentiation, resulting in disorganized growth plates and dysregulated bone growth2 COMPLICATIONSMECHANISM ACH is the most common cause of disproportionate short stature
Page 42
cm/year 876 9543 ~6cm AHV is potentially leaving efficacy on the table 42 Pediatric 7.66 ACH (FGFR3+) ACH ~4.04 Average AHV TransCon CNP 5.7–5.98 ~5’9” 1.76m1 ~4’3” 1.30m2 46cm (18”) Vosoritide (CNP)5.4–5.97 26 cm (10”)3 Per BioMarin 6 Infigratinib 6.05 ~2.7cm/yr avg AHV improvement would be needed over 17 years to reach final average male stature 11 1.7cm>placebo 1.8cm>placebo1.5cm>placebo 1. CDC Vital and Health Statistics (represents average US male and female heights for ages 20-29); 2. Hoover Fong, 2021 (represents average ACH adult male height); 3. Potential total height gain from VOXZOGO BMRN 5/12/25 Press Release; 4. Savarirayan, 2021 (5 to 14yrs); 5. 6.0 AHV from Ph2 Cohort 5 12mo data, Savarirayan, 2024; 6.0 LS mean AHV and 1.7 LS mean absolute AHV improvement vs placebo data based on Ph3 study (n=113), BBIO 2/12/26 Corporate Presentation; infigratinib showed 1.7cm LS mean change from baseline AHV improvement over placebo; 6. Merck Manuals (12mo to 10yrs); 7. 5.4 AHV from Ph2 100 μg/kg/week cohort 6mo data (n=11) Ascendis 11/14/22 Corporate Presentation; 5.9 LS mean AHV and 1.5 LS mean absolute AHV improvement vs placebo data based on Ph3 study (n=84), Savarirayan, 2025; 8. 5.9 from Ph2 Cohort 3 12mo Data (n=10), Savarirayan, 2019; 5.7 LS mean and 1.8 LS mean absolute AHV improvement vs placebo data based on VOXZOGO prescribing information 10/2023 (n=121); VOXZOGO showed 1.6cm LS mean change from baseline AHV improvement over placebo; 9. 19.2 represents AHV for three pediatric oncology case studies with available height velocity data; Sait, 2023; 10. BioMarin 05/04/24 press release; 12mo data from Ph2 (n=8) Investigator initiated study in ISS (ACAN Deficiency, NPR2 Mutation) and Noonan Syndrome 11. Calculation assumes male growth plate c losure at 17 years of age, Sarafoglou, 2009 Further engaging FGFR3 and achieving a higher AHV could potentially benefit key sequelae like reach and gait, and potentially reduce spinal stenosis / surgeries.
Page 43
151413 16121110 191817 20 FGFR3 inhibition has been shown to accelerate height velocity 43 cm/year 876 9543 ACH (FGFR3+) ACH ~4.04 Average AHV Pediatric 7.66 19.296.05 Infigratinib (1/6 oncology dose) Pan-FGFR for Pediatric Oncology (oncology dose causing fractures) HEIGHT PERCENTILES Oncology patients with physiologic growth plate signaling treated with Pan-FGFR inhibitors9 95% 75% 50% 25% 5% 1. CDC Vital and Health Statistics (represents average US male and female heights for ages 20-29); 2. Hoover Fong, 2021 (represents average ACH adult male height); 3. Potential total height gain from VOXZOGO BMRN 5/12/25 Press Release; 4. Savarirayan, 2021 (5 to 14yrs); 5. 6.0 AHV from Ph2 Cohort 5 12mo data, Savarirayan, 2024; 6.0 LS mean AHV and 1.7 LS mean absolute AHV improvement vs placebo data based on Ph3 study (n=113), BBIO 2/12/26 Corporate Presentation; infigratinib showed 1.7cm LS mean change from baseline AHV improvement over placebo; 6. Merck Manuals (12mo to 10yrs); 7. 5.4 AHV from Ph2 100 μg/kg/week cohort 6mo data (n=11) Ascendis 11/14/22 Corporate Presentation; 5.9 LS mean AHV and 1.5 LS mean absolute AHV improvement vs placebo data based on Ph3 study (n=84), Savarirayan, 2025; 8. 5.9 from Ph2 Cohort 3 12mo Data (n=10), Savarirayan, 2019; 5.7 LS mean and 1.8 LS mean absolute AHV improvement vs placebo data based on VOXZOGO prescribing information 10/2023 (n=121); VOXZOGO showed 1.6cm LS mean change from baseline AHV improvement over placebo; 9. 19.2 represents AHV for three pediatric oncology case studies with available height velocity data; Sait, 2023; 10. BioMarin 05/04/24 press release; 12mo data from Ph2 (n=8) Investigator initiated study in ISS (ACAN Deficiency, NPR2 Mutation) and Noonan Syndrome 11. Calculation assumes male growth plate c losure at 17 years of age, Sarafoglou, 2009
Page 44
Evidence points to FGFR3 inhibition potential beyond ACH 44 1.76m2 1.30m3 1.96m1 GENETIC PRECLINICAL CLINICAL FGFR3 mutation phenotypes point to a key role in regulating bone growth. FGFR3 inhibition below an IC90 drove hyper-typical growth in WT mice.4 Oncology doses of pan-FGFR drive hyper-typical growth in pediatric cancers.5 ∆46cm TYPICAL ACHCATSHL FGFR3 down-regulated (single allele knockout) FGFR3 up-regulated (G380R alt. overexpression) ∆20cm HEIGHT PERCENTILES Pediatric oncology patients with physiologic growth plate signaling treated with Pan- FGFR inhibitors 3 95% 75% 50% 25% 5% 18 16 14 12 10 8 6 4 2 0 Oncology dose 8.2% femur length Dabogratinib dose mg/kg Stat. sig. long bone 1. Toydemir, 2026; 2. CDC Vital and Health Statistics (represents average US male and female heights for ages 20-29); 3. Hoover-Fong, 2021 (represents average ACH adult male height); 4. Starett, 2025; 5. Sait, 2023
Page 45
Safety sentinel cohort expanded with DL5 in Ph2 BEACH301 45*Dose decisions based on 6 participants. Additional participants may be assigned at discretion of Sponsor Sentinel Safety Cohort ACH age 5-10 No run-in 0.50 0.375 0.25 0.125 DOSE (mg/kg) *Cohort 1 (6-mo run-in) Treatment naïve; ACH age 3-10 0.625 0.50 0.375 0.25 DOSE (mg/kg) Natural Hx (6 mo)0 6 12 *Cohort 2 (6-mo run-in) Received prior growth-accelerating therapy; ACH age 3-10 months on treatment Cohorts 1 and 2* 0.625 0.125 Anticipate n=~25 total enrollment 6 6 6 6 N=* 6
Page 46
SKELETAL DYSPLASIA Achondroplasia (~3K) Hypochondroplasia (~2K) Thanatophoric dysplasia SADDAN syndrome Double dominant ACH CRANIOSYNOSTOSIS Crouzon syndrome with acanthosis nigricans Muenke syndrome 46 FGFR3 GERMLINE MUTATIONS OTHER GENETIC SHORT STATURE Leri-Weill dyschondrosteosis (~26K) Turner syndrome (~10K) Osteogenesis imperfecta (~4K) Mucopolysaccharidoses IVA and VI Laron syndrome (Growth Hormone Insensitivity) Addressable US pediatric population; Source: company research 1. Represents children ages 4-17 under 2.25 standard deviations from mean height PEDIATRIC SHORT STATURE Genetic and Idiopathic short stature (~700K1)ODD & RPD granted There are many development opportunities beyond ACH and HCH
Page 47
Gearing up for potential pivotal trials in 3 blockbuster indications 47 Differentiated Molecule 3 Potential Blockbuster Indications Validated Target FGFR3 alterations drive conditions with high unmet needs IR NMIBC – Adjuvant Ph3 Initiation EXPECTED 2027 NASDAQ: TYRA CASH: $353.9M (As of 2Q26) ACH – Initial results (n=~25 sentinel DL1-5) End of 1Q27 LG UTUC – Initial results 2027 The first oral, once-daily, highly selective FGFR3 inhibitor DABOGRATINIB 60mg PoC IR NMIBC Patients All MLs: 79% ORR and 64% BOR CR rate (n=14) Single MLs: 100% ORR & 75% BOR CR rate (n=8) ACH: Achondroplasia; IR NMIBC: Intermediate Risk Non-Muscle-Invasive Bladder Cancer; LG UTUC: Low Grade Upper Tract Urothelial Carcinoma; ML Marker Lesion; ORR: Overall Response Rate; BOR: Best overall Response; CR: Complete Response; DL: Dose Level All TYRA small molecule inhibitors are for investigational use only